CDKN2A and renal cell carcinoma: Interestingly, p14ARF promoter methylation had a higher OR value (OR = 11.73) than that of p16INK4A promoter methylation (OR = 2.77) in cancer patients versus control patients, suggesting that RCC can be more susceptible to p14ARF promoter methylation.